Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Viridian Therapeutics, Inc.\DE (VRDN) Debt to Equity (2016 - 2025)

Viridian Therapeutics, Inc.\DE (VRDN) has 9 years of Debt to Equity data on record, last reported at $0.04 in Q3 2025.

  • For Q3 2025, Debt to Equity rose 43.18% year-over-year to $0.04; the TTM value through Sep 2025 reached $0.04, up 43.18%, while the annual FY2024 figure was $0.03, 32.96% down from the prior year.
  • Debt to Equity reached $0.04 in Q3 2025 per VRDN's latest filing, up from $0.04 in the prior quarter.
  • Across five years, Debt to Equity topped out at $0.05 in Q4 2023 and bottomed at $0.03 in Q3 2024.
  • Average Debt to Equity over 3 years is $0.04, with a median of $0.04 recorded in 2024.
  • Peak YoY movement for Debt to Equity: plummeted 32.96% in 2024, then soared 43.18% in 2025.
  • A 3-year view of Debt to Equity shows it stood at $0.05 in 2023, then tumbled by 32.96% to $0.03 in 2024, then surged by 35.53% to $0.04 in 2025.
  • Per Business Quant database, its latest 3 readings for Debt to Equity were $0.04 in Q3 2025, $0.04 in Q2 2025, and $0.03 in Q1 2025.